がん情報サイト | がん情報各論:[医療専門家向け],Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma | Journal of Clinical Oncology,476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results | Journal for ImmunoTherapy of Cancer,メジカルビュー社|看護師|図説CTGテキスト アドバンス,難治性がん治療に向けた核酸医薬の開発 (Development of nucleic acid therapeutics for the treatment of intractable cancer) | 大阪大学×SDGs,